Although a reliable biomarker is desired to identify the gastric cancer patients who are candidates for FGFR2 targeting therapy, however suitable FGFR2 antibodies that are specific for the FGFR2IIIb and FGFR2IIIc types are not yet available, so far. The gene discussed is FGFR2; the disease is gastric cancer.